LONG-TERM SAFETY OF OFLOXACIN AND CIPROFLOXACIN IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS

被引:40
作者
BERNING, SE
MADSEN, L
ISEMAN, MD
PELOQUIN, CA
机构
[1] NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206
[2] NATL JEWISH CTR IMMUNOL & RESP MED,DEPT NURSING,DENVER,CO 80206
[3] UNIV COLORADO,SCH MED,DENVER,CO
[4] UNIV COLORADO,SCH PHARM,DENVER,CO
关键词
D O I
10.1164/ajrccm.151.6.7767552
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Ofloxacin and ciprofloxacin are potentially useful agents for treating mycobacterial infections. We retrospectively reviewed 7 years' experience with these agents in 103 patients, Ofloxacin was used primarily to treat tuberculosis (TB), dosed to achieve 2-hour postdose serum concentrations of 8-12 mu g/ml. Ciprofloxacin was used primarily to treat Mycobacterium avium complex (MAC) infection, dosed to achieve 2-hour postdose serum concentrations of 4-6 mu g/ml. Despite differences in patient characteristics, underlying disease, and concurrent medications, ofloxacin and ciprofloxacin were associated with a similar spectrum and incidence of adverse reactions. Both drugs were generally well tolerated. Adverse effects led to an ofloxacin dosage change in 1 patient (3%) and discontinuation of ofloxacin in 2 patients (6%). Adverse effects led to a ciprofloxacin dosage change in 2 patients (3%) and discontinuation of ciprofloxacin in 5 patients (7%). Ofloxacin and ciprofloxacin appear to be tolerated as well as or better than other ''second-line'' antimycobacterial drugs.
引用
收藏
页码:2006 / 2009
页数:4
相关论文
共 16 条
[1]  
BALL P, 1989, REV INFECT DIS, V11, pS1365
[2]   CIPROFLOXACIN - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE [J].
CAMPOLIRICHARDS, DM ;
MONK, JP ;
PRICE, A ;
BENFIELD, P ;
TODD, PA ;
WARD, A .
DRUGS, 1988, 35 (04) :373-447
[3]   LOW SERUM LEVELS OF ORAL ANTIMYCOBACTERIAL AGENTS IN PATIENTS WITH DISSEMINATED MYCOBACTERIUM-AVIUM COMPLEX DISEASE [J].
GORDON, SM ;
HORSBURGH, CR ;
PELOQUIN, CA ;
HAVLIK, JA ;
METCHOCK, B ;
HEIFETS, L ;
MCGOWAN, JE ;
THOMPSON, SE .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06) :1559-1562
[4]  
Heifets LB, 1991, DRUG SUSCEPTIBILITY, P13
[5]  
ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108
[6]   RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF RIFAMPIN, ETHAMBUTOL, AND CIPROFLOXACIN FOR AIDS PATIENTS WITH DISSEMINATED MYCOBACTERIUM-AVIUM COMPLEX INFECTION [J].
JACOBSON, MA ;
YAJKO, D ;
NORTHFELT, D ;
CHARLEBOIS, E ;
GARY, D ;
BROSGART, C ;
SANDERS, CA ;
HADLEY, WK .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (01) :112-119
[7]   CIPROFLOXACIN IN PATIENTS WITH MYCOBACTERIAL INFECTIONS - EXPERIENCE IN 15 PATIENTS [J].
KAHANA, LM ;
SPINO, M .
DICP-THE ANNALS OF PHARMACOTHERAPY, 1991, 25 (09) :919-924
[8]   EARLY BACTERICIDAL AND STERILIZING ACTIVITIES OF CIPROFLOXACIN IN PULMONARY TUBERCULOSIS [J].
KENNEDY, N ;
FOX, R ;
KISYOMBE, GM ;
SARUNI, AOS ;
UISO, LO ;
RAMSAY, ARC ;
NGOWI, FI ;
GILLESPIE, SH .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 148 (06) :1547-1551
[9]   SAFETY PROFILE OF CIPROFLOXACIN DURING LONG-TERM THERAPY FOR PULMONARY TUBERCULOSIS [J].
KENNEDY, N ;
FOX, R ;
UISO, L ;
NGOWI, FI ;
GILLESPIE, SH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (06) :897-902
[10]  
KOHNO S, 1992, CHEST, V102, P1816